NMN (nicotinamide mononucleotide)
Precursor of NAD, sold as an anti-ageing product.
What the research shows
No sound research in humans.
Chen (2024) pooled 8 trials with 342 mostly healthy adults and found no effect on fasting glucose, insulin, HbA1c or blood lipids. Yi (2023) mainly measured the blood NAD concentration in 80 participants, a surrogate marker, in a study with authors from the NMN producer. Wang (2025) saw small differences in walking speed and liver values across 9 studies with 412 participants.
Who it makes sense for: Nobody demonstrably: the outcomes measured are lab values without any demonstrated health gain.
How we weigh evidenceClinical dosage
Scientific sources
The clinical dosages on this page are based on peer-reviewed research.
- Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials.Chen F et al. (2024)
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.Yi L et al. (2023)Funded by: Eerste auteur is werknemer van Abinopharm, Inc.; twee co-auteurs zijn werknemers van Aba Chemicals, de producent van het geteste NMN.
- Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-aged and Elderly: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Wang JP et al. (2025)
We keep the dosages and values on this page as accurate as possible based on selected studies. New research may change these values. Nothing on this page is medical advice. If you have any doubts, always consult a doctor.